• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

芬太尼透皮吸收与接受姑息治疗患者的药代动力学特征相关。

Fentanyl transdermal absorption linked to pharmacokinetic characteristics in patients undergoing palliative care.

机构信息

Katholieke Universiteit Leuven, Department of Occupational, Environmental and Insurance Medicine, B-3000 Leuven, Belgium.

出版信息

J Clin Pharmacol. 2010 Jun;50(6):667-78. doi: 10.1177/0091270009347872. Epub 2010 Jan 23.

DOI:10.1177/0091270009347872
PMID:20097932
Abstract

Delivery rates and plasma concentrations vary among patients treated with fentanyl patches. Absorption and urinary excretion characteristics of fentanyl were studied in patients undergoing palliative care. Almost 500 patches were analyzed for residual fentanyl content. Fentanyl and norfentanyl levels were determined in the urine of 50 patients. General and mixed effects linear regression models were established for the relationship between fentanyl dose rate and urinary excretion and to incorporate influencing factors. For different patch nominal dose strengths, wide but comparable variability in estimated dose rate and delivery efficiency was observed (coefficients of variation of 15% to 17%). Fentanyl delivery efficiency was 8.5% higher for patches of 25 microg/h as compared to 75 microg/h and, accordingly, 7.5% for patch application on the arm as compared to the leg. Urinary fentanyl and norfentanyl concentrations varied considerably. The general linear model revealed a positive effect of the calculated transdermal dose rate on urinary fentanyl levels, explaining 34% of the variability (P < .0001). In addition, gender (P = .04) and type of cancer pathology (P = .03) exerted significant effects on the linear model, explaining 40% and 64% of the variability, respectively. Delivery efficiency of fentanyl patches can vary substantially, possibly leading to either underdosing or overdosing.

摘要

接受芬太尼贴剂治疗的患者之间,其药物释放率和血药浓度存在差异。我们研究了接受姑息治疗的患者中芬太尼的吸收和尿排泄特征。对近 500 片芬太尼贴剂进行了残留芬太尼含量分析。对 50 名患者的尿液进行了芬太尼和去甲芬太尼水平检测。建立了芬太尼剂量率与尿排泄之间的关系以及纳入影响因素的通用和混合效应线性回归模型。对于不同的贴剂标称剂量强度,估计的剂量率和释放效率存在广泛但可比的变异性(变异系数为 15%至 17%)。与 75μg/h 的贴剂相比,25μg/h 的贴剂的释放效率高 8.5%,相应地,与腿部贴剂相比,手臂贴剂的释放效率高 7.5%。尿中芬太尼和去甲芬太尼浓度差异很大。一般线性模型显示,经皮剂量率的计算对尿中芬太尼水平有正效应,可解释 34%的变异性(P<0.0001)。此外,性别(P=0.04)和癌症病理类型(P=0.03)对线性模型有显著影响,分别解释了 40%和 64%的变异性。芬太尼贴剂的释放效率可能会有很大差异,这可能导致剂量不足或过量。

相似文献

1
Fentanyl transdermal absorption linked to pharmacokinetic characteristics in patients undergoing palliative care.芬太尼透皮吸收与接受姑息治疗患者的药代动力学特征相关。
J Clin Pharmacol. 2010 Jun;50(6):667-78. doi: 10.1177/0091270009347872. Epub 2010 Jan 23.
2
Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients.癌症疼痛患者经皮芬太尼吸收的个体间和个体内变异性。
Oncol Rep. 2005 Oct;14(4):1029-36.
3
A Phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic nonmalignant pain.一项评估低剂量芬太尼透皮系统在慢性非恶性疼痛患者中的临床应用价值的Ⅲ期研究。
Curr Med Res Opin. 2006 Aug;22(8):1493-501. doi: 10.1185/030079906X115540.
4
Transdermal fentanyl matrix patches Matrifen and Durogesic DTrans are bioequivalent.经皮芬太尼基质贴片 Matrifen 和 Durogesic DTrans 具有生物等效性。
Eur J Pharm Biopharm. 2010 Jun;75(2):225-31. doi: 10.1016/j.ejpb.2010.02.005. Epub 2010 Feb 10.
5
Improved cancer pain treatment using combined fentanyl-TTS and tramadol.使用芬太尼透皮贴剂与曲马多联合用药改善癌症疼痛治疗
Pain Pract. 2007 Dec;7(4):307-12. doi: 10.1111/j.1533-2500.2007.00155.x. Epub 2007 Nov 6.
6
Transdermal fentanyl in cachectic cancer patients.恶病质癌症患者的透皮芬太尼
Pain. 2009 Jul;144(1-2):218-22. doi: 10.1016/j.pain.2009.04.012. Epub 2009 May 12.
7
LC-MS/MS analysis of fentanyl and norfentanyl in a fatality due to application of multiple Durogesic transdermal therapeutic systems.在因使用多个多瑞吉透皮治疗系统导致死亡的案例中对芬太尼和去甲芬太尼进行液相色谱-串联质谱分析。
Forensic Sci Int. 2007 Jul 4;169(2-3):223-7. doi: 10.1016/j.forsciint.2006.03.018. Epub 2006 May 2.
8
Low doses of transdermal fentanyl in opioid-naive patients with cancer pain.低剂量经皮芬太尼用于阿片类药物初治的癌症疼痛患者。
Curr Med Res Opin. 2010 Dec;26(12):2765-8. doi: 10.1185/03007995.2010.532545. Epub 2010 Nov 1.
9
Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain.影响癌症患者生活质量的因素:透皮芬太尼在疼痛管理中的作用。
Semin Oncol. 1998 Jun;25(3 Suppl 7):47-53.
10
Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.癌症疼痛患者从透皮芬太尼转换为口服美沙酮的阿片类药物转换
Cancer. 2004 Dec 15;101(12):2866-73. doi: 10.1002/cncr.20712.

引用本文的文献

1
Is personal physiology-based rapid prediction digital twin for minimal effective fentanyl dose better than standard practice: a pilot study protocol.基于个人生理特征的最小有效芬太尼剂量快速预测数字化双胞胎是否优于标准实践:一项初步研究方案。
BMJ Open. 2024 Sep 24;14(9):e085296. doi: 10.1136/bmjopen-2024-085296.
2
Does transdermal fentanyl work in patients with low BMI? Patient-reported outcomes of pain and percent pain relief in cancer patients on transdermal fentanyl.经皮芬太尼在低 BMI 患者中有效吗?接受经皮芬太尼治疗的癌症患者的疼痛和疼痛缓解百分比的患者报告结局。
Cancer Med. 2019 Dec;8(18):7516-7522. doi: 10.1002/cam4.2479. Epub 2019 Sep 30.
3
Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanyl.
阿瑞匹坦及贴片位置对使用透皮芬太尼的癌症患者芬太尼暴露量的影响。
Oncotarget. 2018 Apr 6;9(26):18269-18276. doi: 10.18632/oncotarget.24812.
4
A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients.解释芬太尼药代动力学变异性的因素综述;重点关注对癌症患者的影响。
Br J Clin Pharmacol. 2017 Feb;83(2):294-313. doi: 10.1111/bcp.13129. Epub 2016 Oct 29.